Graham Hetherington

Chair

Graham brings substantial financial and industry experience to the Board having served as the Chief Financial Officer of two FTSE 100 companies.  He has a wide knowledge of international finance management and planning, including M&A and audit and risk management coupled with an in-depth understanding of the US market.

Until recently, Graham was Chair of the Audit Committee of BTG plc, a global healthcare company, from 2016 and Senior Independent Director from 2017. He was previously Chief Financial Officer of Shire PLC, a global pharmaceutical company from 2008 until 2014, Chief Financial Officer of Bacardi and Company between 2007-08 and Chief Financial Officer of Allied Domecq plc from 1999 to 2005.
 

Graham is a Fellow of the Chartered Institute of Management Accountants.

• Chair of the Nomination & Governance Committee
• Member of the Remuneration Committee

Mark Crossley

Chief Executive Officer

Mark was appointed Chief Executive Officer in June 2020.

Mark was appointed to the Board and as Chief Financial Officer in February 2017. In July 2019, Mark took on additional responsibilities and was appointed Chief Financial and Operations Officer in July 2019, with oversight of the finance, information technology, manufacturing, supply, quality and procurement functions.

He joined the Company in 2012 as the Global Finance Director with responsibilities for Finance, Information Systems and Procurement. He was appointed Chief Strategy Officer in October 2014.

Prior to joining Indivior, Mark spent 13 years at Procter & Gamble in various finance leadership roles including Corporate Portfolio, Strategic and Business Planning (Female Beauty), as well as multiple roles in Corporate Treasury and its Baby Care division. He also enjoyed an eight-year career with various operational and staff assignments in the United States Coast Guard.

Mark graduated from the United States Coast Guard Academy with a BS in Management and Economics, and from Boston College with an MBA.

Peter Bains

Independent Non-Executive Director

Peter is currently Non-Executive Chair of ILC Therapeutics, a private UK-based biotechnology company and pioneer in the discovery and development of interferon drugs. He is also Group CEO of Biocon Limited, a biopharmaceutical company listed on the National Stock Exchange of India. 

Peter has over three decades of experience in the biotech and pharmaceutical industry, which included a 23-year career at GlaxoSmithKline, where he held numerous senior operational and strategic roles.  He also served as the Representative Executive Officer and Chief Executive Officer of Sosei Group Corporation, a Tokyo listed biotech company, and Chief Executive Officer of Syngene International, which he successfully took public on the Mumbai Exchanges in 2015.

Peter has a BSc Combined (Honours) in Physiology/Zoology from Sheffield University.

• Chair of the Science & Policy Committee
• Member of the Remuneration Committee

Joanna Le Couilliard

Independent Non-Executive Director

Jo Le Couilliard has recently been appointed as Chair of the Remuneration Committee, with effect from October 1, 2023. She is a healthcare industry veteran with 25 years’ healthcare management experience gained in Europe, the US and Asia. Much of her career has been in pharmaceuticals at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and Asia Pacific Pharmaceuticals business and led a program to modernise the commercial model. She was previously Chief Operating Officer at the BMI group of private hospitals in the UK

She currently serves as a Non-Executive Director and Chair of the Audit and Risk Committee at NIOX Group PLC, as a Non-Executive Director and Chair of the Remuneration Committee at Alliance Pharma plc, and as a Non-Executive Director at the Italian listed pharmaceutical company, Recordati S.p.A., where she is also Chair of the Remuneration and Nominations Committee. She has previously served as a Non-Executive Director at Frimley Park NHS Foundation Trust in the UK, Cello Health PLC and at the Duke NUS Medical School in Singapore.

Jo is a Chartered Accountant holding an ACA from the Association of Chartered Certified Accountants and holds a Masters in Natural Sciences from the University of Cambridge.

• Member of the Audit Committee
• Member of the Remuneration Committee

Jerome Lande

Non-Executive Director

Jerome Lande has over 20 years of experience as a professional investor, including substantial investing in medical device, pharmaceutical and healthcare services companies. He currently serves as Head of Special Situations investments at Scopia Capital Management. Jerome co-founded Coppersmith Capital Management, where he was managing partner and portfolio manager until it combined with Scopia in 2016.

Prior to co-founding Coppersmith, Jerome was a partner of MCM Capital Management, LLC, the general partner of MMI Investments, LP, a small-cap investment fund founded in 1996 to employ private equity investing methodologies in public equities, and where Jerome oversaw research, trading and activism from 1998 to 2011. During that time, he was also associated with MCM’s private equity investments wherein he was directly involved with corporate development as well as equity growth. Jerome is a member of the board of directors and Chair of the Strategy Committee of CONMED Corporation, a public global medical technology company.

Jerome is a member of the board of directors of Itron Inc., a public global technology company that offers products and services on energy and water resource management. He is also a Non-Executive Director of R&Q Insurance Holdings Ltd, a global non-life speciality insurance company. Jerome previously served as a member of the board of directors of Forest City Realty Trust, Inc., a public national real estate company. Jerome holds a B.A. from Cornell University.

• Member of the Nomination & Governance Committee

A. Thomas McLellan Ph.D

Independent Non-Executive Director

Tom has been a career researcher for 40 years with the Treatment Research Institute (which he co-founded in 1992) and the University of Pennsylvania. During his career, Tom has published over 550 articles and chapters on addiction research. He has received several awards including Life Achievement Awards from the American, Swedish, Italian, Egyptian and British Societies of Addiction Medicine and from the American Public Health Association.

From 2009 through 2011, Tom was the Deputy Director of the White House Office of National Drug Control Policy, where he was one of the principal authors of the President’s National Drug Control Strategy.

Tom holds a B.A. from Colgate University and an M.S. and Ph.D. from Bryn Mawr College. He received postgraduate training in psychology at Oxford University in England.

• Member of the Nomination & Governance Committee
• Member of the Science & Policy Committee

Lorna Parker

Independent Non-Executive Director

Lorna has been conducting Board Effectiveness reviews for UK public companies for over ten years as an Advisory Partner at Manchester Square Partners and also as an independent consultant. In addition she is a member of the Supervisory Board of PAI Partners SAS, a leading private equity firm headquartered in Paris. She is also a Trustee of the Royal Horticultural Society and of the National Opera Studio. Until recently she was a senior advisor at CVC Capital Partners, providing advice on portfolio company leadership, succession and recruitment. She previously held a similar role at BC Partners.

Lorna’s executive career was primarily in executive recruitment, as a partner at Spencer Stuart. She created and led their private equity practice across Europe, co-led the legal search practice globally, was a member of the UK Board practice and was the UK Managing Partner. Prior to joining Spencer Stuart, Lorna worked for venture capital firm Advent and investment bank Kleinwort Benson.

Lorna has an MA in Economics from Cambridge University and an MBA from Stanford Business School. 
 

• Member of the Nomination & Governance Committee
• Member of the Remuneration Committee

Daniel J. Phelan

Senior Independent Director

Dan currently serves as a Non-Executive Director at Kraton Corporation. Dan spent 31 years at GlaxoSmithKline plc, during which he was an advisor to three chief executives and was a member of the Corporate Executive Team.  Prior to his retirement in December 2012, he was Chief of Staff with global responsibility for Corporate Strategy and Development, Human Resources, Information Technology, Real Estate and Facilities, Environmental Health and Safety, and Security.  Before that, he was Senior Vice-President, Human Resources for fourteen years.   Until recently, Dan was a Board Director of TE Connectivity (formerly Tyco Electronics).  He is an advisor with the GLG Institute.  

Dan is a graduate of Rutgers College. He holds a Master’s degree from The Ohio State University and a law degree from Rutgers University School of Law. He is admitted to practice in New Jersey and Pennsylvania. 

Dan served as an officer on active duty and the reserves in the U.S. Army Medical Service Corps. He has published on CEO succession planning and onboarding and public sector collective bargaining. 

• Chair of the Remuneration Committee
• Member of the Nomination & Governance Committee

Ryan Preblick

Chief Financial Officer

Ryan was appointed Chief Financial Officer and Executive Director in November 2020, having served as Interim Financial Officer since June 2020.  Ryan has been in a financial leadership capacity since joining Indivior in 2012 and prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Finance and Commercial Operations. This included overseeing all key financial management, analysis and reporting elements of the Group’s global business.
 

Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial aspects of the US business, the Group’s largest business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan joined Indivior as US Commercial Controller.
 

Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Phillip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support.
 

Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.

Barbara Ryan

Independent Non-Executive Director

Barbara was a Wall Street sell-side research analyst covering the US Large Cap Pharmaceutical Industry for more than 30 years before founding Barbara Ryan Advisors, a capital markets and communications firm, in 2012. Barbara has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis and corporate strategy across a broad range of life sciences companies. Barbara is also the Founder of Fabulous Pharma Females, a non-profit organization whose mission is to advance women in the biopharma industry.  Barbara is a Senior Advisor at EY and is currently a Non-Executive Director of INVO Bioscience (Nasdaq: INVO) and MINK Therapeutics (Nasdaq: INKT).

• Member of the Audit Committee
   
• Member of the Science and Policy Committee

Mark Stejbach

Independent Non-Executive Director

Mark Stejbach has over 30 years of experience in biotech and pharmaceuticals, including senior roles in a broad range of commercial functions including marketing, sales, economic affairs, managed care and finance. Mark most recently served as Senior Vice President and Chief Commercial Officer at Alkermes, plc, a publicly traded global biopharmaceutical company, where he was responsible for building sales of Vivitrol from ~$40m to ~$300m.

Prior to his role at Alkermes, Mark served as the Chief Commercial Officer at Tengion, Inc. from 2008 to 2012, and he previously held senior positions at Merck and Biogen.  He served as a non-executive director on the board of Flexion Therapeutics (NASDAQ: FLXN), from 2016 until its acquisition in 2021.  Flexion marketed a “buy-and-bill” long-acting injectable for the treatment of osteoarthritis.  He also previously served as Senior Commercial Advisor to EIP Pharma Inc., a private company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases.

Mark holds an M.B.A. from the Wharton School, University of Pennsylvania and a B.S. in mathematics from Virginia Tech.
 

• Member of the Audit Committee
• Member of the Science & Policy Committee

Juliet Thompson

Independent Non-Executive Director

Juliet Thompson has recently been appointed as Senior Independent Director with effect from October 1, 2023. She has over 30 years of finance, banking and board experience with significant focus in the healthcare sector. Juliet is a proven FTSE 250 audit chair and a former investment banker who has spent her career advising pharmaceutical companies. She played a leading role in setting up Code Securities, which was quickly acquired by Nomura (becoming Nomura Code) but remained independent. At Nomura Code, Juliet was advising companies in the healthcare and clean tech sectors on their financing and strategic options. She worked on over 50 transactions including IPO’s, secondary offerings, private placements and M&A. As Nomura Code was devolved, she joined Stifel with a team from Nomura Code to head up the life sciences and clean tech teams where she advised CEOs and CFOs in the healthcare sector.

Since retiring, Juliet has built a diverse portfolio; she currently chairs the Audit Committee of Novacyt, she is a Non-Executive Director of Organox and is also a Non-Executive Director of Angle PLC. She previously served on the Board of GI Dynamics, a Boston-based medical device company developing products for patients with type 2 diabetes and obesity. She holds a BSc in Economics from the University of Bristol and is a Chartered Accountant holding an ACA from the Association of Chartered Certified Accountants.

• Chair of the Audit Committee
• Member of the Nomination & Governance Committee

Mark Crossley

Chief Executive Officer

Mark was appointed Chief Executive Officer in June 2020.

Mark was appointed to the Board and as Chief Financial Officer in February 2017. In July 2019, Mark took on additional responsibilities and was appointed Chief Financial and Operations Officer in July 2019, with oversight of the finance, information technology, manufacturing, supply, quality and procurement functions.

He joined the Company in 2012 as the Global Finance Director with responsibilities for Finance, Information Systems and Procurement. He was appointed Chief Strategy Officer in October 2014.

Prior to joining Indivior, Mark spent 13 years at Procter & Gamble in various finance leadership roles including Corporate Portfolio, Strategic and Business Planning (Female Beauty), as well as multiple roles in Corporate Treasury and its Baby Care division. He also enjoyed an eight-year career with various operational and staff assignments in the United States Coast Guard.

Mark graduated from the United States Coast Guard Academy with a BS in Management and Economics, and from Boston College with an MBA.

Ryan Preblick

Chief Financial Officer

Ryan was appointed Chief Financial Officer and Executive Director in November 2020, having served as Interim Financial Officer since June 2020.  Ryan has been in a financial leadership capacity since joining Indivior in 2012 and prior to his appointment as Interim Chief Financial Officer in June 2020, Ryan was Senior Vice President, Global Finance and Commercial Operations. This included overseeing all key financial management, analysis and reporting elements of the Group’s global business.
 

Prior to that, Ryan was Vice President, US Finance with responsibility overseeing all financial aspects of the US business, the Group’s largest business, including management, planning, analysis and reporting, government pricing and managed care contracting operations. Ryan joined Indivior as US Commercial Controller.
 

Ryan started his career in corporate finance at Honeywell International and then spent twelve years at Altria Company (including Phillip Morris USA) in finance leadership roles of increasing responsibility working with Treasury, Financial Planning & Analysis, Market Analytics, Supply Chain and Brand Decision Support.
 

Ryan holds a BS in Finance from Penn State University and an MBA from the University of Richmond.

Jeffrey Burris

Chief Legal Officer

Jeff was appointed Chief Legal Officer in December 2021.  He brings nearly 25 years of extensive legal, life sciences and public company experience to Indivior, including over 13 years as the head of the legal function at various life sciences companies. 

Jeff joined Indivior from Arbor Pharmaceuticals where he was Vice President, General Counsel, Chief Compliance Officer and Secretary.  Prior to that he was Vice President, General Counsel, Chief Compliance Officer and Secretary at Alimera Sciences, a publicly traded pharmaceutical company, and Vice President, General Counsel and Chief Compliance Officer at CryoLife, a publicly traded biotechnology company.  
 
Jeff started his career in the corporate law group at Arnall Golden Gregory LLP focused on mergers, acquisitions, divestitures, contracting and licensing work.  He then moved in-house to Waste Management, where he was Senior Counsel focused primarily on acquisitions and divestitures of Waste Management’s Southern Group.  
 
Jeff holds a BA in History and Economics from the University of Tennessee and a JD from The University of Chicago Law School.

Cynthia (Cindy) Cetani

Chief Integrity and Compliance Officer

In October 2018, Cindy was appointed as Chief Integrity & Compliance Officer for Indivior.  Cindy brings to Indivior 31 years of U.S. and global leadership in the pharmaceutical industry, with the diversity of cross-industry experience spanning managed care, life and health insurance.   The majority of her career has been dedicated to driving a culture of learning and integrity, and compliance program vision, while enabling innovation and patient-focused business results.
 

Cindy joined Indivior from Novartis Pharmaceuticals Corp (NPC) where she held roles of increasing responsibility over 15 years of service.  Cindy joined NPC in 2003 as Associate Director, Healthcare Compliance.  Initially focused on the U.S. pharmaceutical and oncology businesses, Cindy built a team of over 50 professionals and was responsible for harmonizing compliance across all the U.S. based Novartis divisions as Chief Compliance Officer NPC and U.S. Country Compliance Head.  In this role she led the development of a robust, effective compliance program and successful implementation of NPC’s 5-year Corporate Integrity Agreement with the Department of Health and Human Services Office of Inspector General.  As a member of the NPC Executive Committee, and the Global and International Compliance leadership teams, she co-led strategic priority development and execution.
 

In her most recent role, Cindy took on an international role as Head of Compliance Operations, Group Integrity & Compliance at the Novartis headquarters in Basel, Switzerland.  There, she developed the strategy for the evolution of the compliance program and new central operations support across all global divisions and 160 countries, while leading the compliance analytics approach for effective risk management and program measurement.  Before joining Novartis, Cindy was Director of Operations, Managed Markets at Pharmacia, led Advertising Compliance for Prudential Healthcare, and held various managerial roles at US Life Insurance and Mutual Benefit Life Insurance companies.
 

Cindy is a Licensed Professional of Ethics & Compliance, and holds a Bachelor of Science, Commerce, Finance – Magna Cum Laude from Rider College, Lawrenceville, New Jersey.

Nina DeLorenzo

Chief Global Impact Officer

Nina was appointed Chief Global Impact Officer in May 2022. She is responsible for creating and advancing the overall global impact and corporate affairs strategy with particular focus on public affairs, government affairs, communications, policy, advocacy, and stakeholder engagement. In addition, Nina will help to develop and lead the company’s environmental, social, and governance strategy.

Nina brings over 25 years of extensive public affairs, communications, policy, and government affairs experience to Indivior.  Immediately prior to joining the company, Nina was senior vice president of global communications and public affairs for Emergent BioSolutions where she led all aspects of corporate communications including branding, advertising, reputation, crisis, media relations, content and storytelling, and employee communications.  She was also responsible for citizenship, philanthropy, and third-party alliance building.  Her previous experience also includes overseeing operations and engagement for a global organization of 450 external affairs professionals at Sanofi in Paris and leading international government affairs and other public policy functions at AbbVie. She also held various senior government and public affairs roles at Pfizer Inc., Schering-Plough Corp. (now Merck), and the Pharmaceutical Research and Manufacturers of America (PhRMA).

Prior to her career in the pharmaceutical industry, Nina served in the administration of President George W. Bush, working in the White House Coalition Information Center at the outset of the war on terror. She also served in the Bureau of International Information Programs at the U.S. Department of State, and worked in the United States Senate and on political campaigns.

Nina obtained her bachelor’s degree in government and international relations from the University of Notre Dame and went on to obtain her master’s degree in international relations from the University of Chicago.

Jon Fogle

Chief Human Resources Officer

In October 2014, Jon was appointed Chief Human Resource Officer for Indivior. Jon joined Reckitt Benckiser as Human Resources Director for the US in 2007. In 2010, he was promoted to Global Human Resources Director. Under his leadership, the company has grown rapidly from just over 200 employees in three countries to more than 900  employees in more than 40 countries. Working with the entire leadership team, Jon has fostered a strong commitment to developing both RBP’s culture and talent.
 

Prior to joining RBP, Jon was Senior Vice President of Human Resources, North America for Capmark Finance (formerly GMAC Commercial Mortgage).
 

Jon holds a BS in psychology from Ursinus College and is a SHRM Senior Certified Professional.

Christian Heidbreder

Chief Scientific Officer

Christian combines 30 years leadership experience in the neurosciences spanning the academic, governmental, and industrial sectors across Europe and the US. During his career, Christian has published over 350 peer-reviewed scientific publications, reviews, book chapters, and published conference proceedings.

Christian began his career as a researcher at the University of Louvain in Belgium, at the National Institute on Drug Abuse in Baltimore, at Princeton University, and at the Swiss Federal Institute of Technology in Zürich. Christian subsequently held positions of increasing responsibility at SmithKline-Beecham’s Neuroscience Department in Harlow (UK), GSK’s R&D Centre of Excellence for Drug Discovery in Psychiatry in Verona (Italy), and Altria Client Services’ Health Sciences Department in Richmond, Virginia.
 

Christian was appointed Global R&D Director at RBP in 2009 with a remit to lead global strategies (including Strategic Portfolio Management, Preclinical and Clinical Development, Chemistry, Manufacturing & Controls, and Regulatory Affairs) to drive the development of new pharmacotherapies in the area of addiction and related co-morbidities.
 

Christian holds BA, MA, and PhD degrees from the University of Louvain and a Certificate in Strategic Innovation from the Wharton Business School. He is an Affiliate Professor in the Department of Pharmacology & Toxicology of the Virginia Commonwealth University School of Medicine since 2010. He is also a Governance Fellow of the National Association of Corporate Directors (NACD) since 2014. In 2018, Christian was appointed by Alex M. Azar II, Secretary of Health and Human Services (HHS), to serve as a member of the National Advisory Council on Drug Abuse (NACDA). The same year Christian was also appointed by Dr. Francis Collins, Director of the National Institutes of Health (NIH), to the Helping to End Addiction Long-term (HEAL) Multi-Disciplinary Working Group (MDWG) focused on a federal effort to speed scientific solutions to stem the opioid crisis.

Kathryn Hudson

Company Secretary

Kathryn is a Chartered Secretary who has over twenty years of experience working for UK listed companies. Prior to joining Indivior, Kathryn was Company Secretary of Kingfisher plc, one of Europe’s largest retailers and Deputy Company Secretary of Burberry Group plc. Kathryn is a fellow of the Chartered Governance Institute.

Vishal Kalia

Chief Strategy Officer

Richard Simkin

Chief Commercial Officer

Richard has over 20 years’ global commercial business experience. He began his career with Reckitt & Colman in 1987 and has held various roles in operations, sales and marketing with increasing responsibility. In addition to his Commercial responsibilities, he took over responsibility for the Global Strategy function in 2017.
 

Prior to his role with RBP, Richard held the position of Global Category Director for one of the core categories within the RB Group where he was responsible for driving strategy and new product development. In addition, he has extensive experience in the healthcare markets ranging from over the counter to prescription products in multiple categories and countries. Richard has also held a number of general manager positions within the RB Group, most recently as General Manager, Portugal in 2008.
 

In 2012 Richard was appointed President, North America of RBP and moved to the US where he currently leads the Commercial organizations in North America, Europe Middle East Africa, Greater China and AustralAsia in successfully navigating the introduction of market competition along with the preparation of pre-launch activities related to the product pipeline.
 

Richard holds an MBA from the University of Lincoln (formerly known as the University of Lincolnshire and Humberside).

Hillel West

Chief Manufacturing and Supply Officer

In February 2020, Hillel was appointed Chief Manufacturing and Supply Officer at Indivior.
 

Hillel brings to Indivior more than 25 years of experience in Operations Management, Strategy and Business Development across US, Europe, Asia-Pacific and emerging markets.
 

He joined Indivior from Teva Pharmaceuticals where he held roles of increasing responsibility over his 14-year tenure including Head of Specialty Medicines Supply, Head of Global Supply Chain and Operations Strategy, and VP – Integration and Separation Management. Previously, he was a senior director at PwC Management Consulting for 9 years in New York, Israel and Czech Republic, partnering with a number of US Fortune 500 CPG, Food and Pharma manufacturers leading engagements in Supply Chain strategy, Organizational and Process transformation.
 

Hillel holds a Bachelor of Chemical Engineering (Hons) from Monash University, Australia and an MBA from Columbia University, NY.